Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meloxicam + esomeprazole
- Development stage
- Unknown
- Lead developer
- Axsome Therapeutics
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Meloxicam + esomeprazole is a fixed-dose oral combination drug consisting of meloxicam, a long-acting nonsteroidal anti-inflammatory drug (NSAID) with preferential cyclooxygenase-2 (COX-2) inhibition, and esomeprazole, a proton pump inhibitor (PPI). Meloxicam provides anti-inflammatory, analgesic, and antipyretic effects primarily by inhibiting prostaglandin synthesis via COX enzymes. Esomeprazole reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase in gastric parietal cells. The rationale for this combination is to provide effective pain relief while reducing the risk of NSAID-induced gastrointestinal ulcers or other GI adverse events through gastric protection. This formulation is being developed for chronic pain conditions such as osteoarthritis and rheumatoid arthritis[2][3][4].
- Brand names
- AXS-06AXS06AXS 06
- Other names
- MoSEIC meloxicam and esomeprazolefixed combination tablets of meloxicam and esomeprazole
02
Targets
ATP1A (Sodium/potassium-transporting ATPase)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on meloxicam + esomeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meloxicam + esomeprazole.